This unexpected outcome, particularly in microenvironments with elevated FGF ligand levels [58], could have detrimental clinical effect in patients, such as ER + breast cancer patients with high FGFR1 and FGF2 expression. This evidence concerns the gene FGFR1 and breast carcinoma.